Skip to main content
Premium Trial:

Request an Annual Quote

Diazyme Inks US Distribution Deal for Maccura Biotechnology Coronavirus Test

NEW YORK — Diazyme Laboratories said on Thursday that it signed an agreement to market and distribute Maccura Biotechnology's SARS-CoV-2 molecular diagnostic in the US.

Specific terms of the deal were not disclosed.

The fluorescent PCR-based test, which received Emergency Use Authorization (EUA) from the US Food and drug Administration in April, is designed to detect the SARS-CoV-2 ORF1ab, N, and E genes in upper respiratory specimens. It runs on Thermo Fisher Scientific's Applied Biosystems 7500 RT-PCR system and may be used by any lab CLIA-certified to perform high-complexity tests, according to Chengdu, China-based Maccura.

Earlier this month, Poway, California-based Diazyme received EUA for its SARS-CoV-2 antibody test.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.